{"nctId":"NCT01626872","briefTitle":"Long-Term Study of MP-214 in Patients With Schizophrenia","startDateStruct":{"date":"2012-09"},"conditions":["Schizophrenia"],"count":254,"armGroups":[{"label":"MP-214 3mg","type":"EXPERIMENTAL","interventionNames":["Drug: MP-214 3mg"]},{"label":"MP-214 6mg","type":"EXPERIMENTAL","interventionNames":["Drug: MP-214 6mg"]},{"label":"MP-214 9mg","type":"EXPERIMENTAL","interventionNames":["Drug: MP-214 9mg"]},{"label":"Risperidone 4mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Risperidone 4mg"]}],"interventions":[{"name":"MP-214 3mg","otherNames":[]},{"name":"MP-214 6mg","otherNames":[]},{"name":"MP-214 9mg","otherNames":[]},{"name":"Risperidone 4mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent obtained from the patient before the completion of Study A002-A4\n* Patients who have completed the A002-A4 study\n\nExclusion Criteria:\n\n* Patients who are experiencing ongoing, uncontrolled, clinically significant adverse events (AEs), as judged by the investigator (or subinvestigator)\n\nThe information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events as a Measure of Safety and Tolerability","description":"The Numbers show Subjects with at least one Adverse Event","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"50","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":81},"commonTop":["Nasopharyngitis","Schizophrenia","Akathisia","Insomnia","Constipation"]}}}